Long-term follow-up study for sickle cell disease treatment
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study is a follow-up for people with sickle cell disease who already saw a benefit in fetal hemoglobin from the earlier Pioneer study. It tests the long-term safety and effects of the study drug pociredir (also called FTX-6058) while allowing most standard sickle cell treatments except hydroxyurea.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in and finished the earlier Pioneer study for this drug.
- Your fetal hemoglobin (HbF) levels improved in that prior study.
- You are at least 18 years old.
- You have not needed more than 24 hours of hospital care for a sickle cell complication in the last 14 days.
- You have not had major surgery, a serious illness, stroke, or seizure in the last 14 days.
- If you are a woman who can become pregnant, you agree to use two effective birth control methods or be abstinent from now until 90 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects feedback through surveys, interviews, and focus groups from people affected by sickle cell disease. Your input helps the research team improve how genomic and gene-therapy information and needs are understood for patients and caregivers.
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
This trial program studies sickle cell disease and how treatment works, especially for people who are already taking hydroxyurea at a stable, maximum tolerated dose. It may help researchers better understand treatment effects and side effects in real patients.
This study is a long-term follow-up for people who already received gene therapy for sickle cell disease in a specific sponsor’s clinical trial. It helps researchers watch for long-term safety and outcomes over time.
This trial tests a drug that helps your body release stem cells so they can be collected for a future bone marrow transplant. It may help make the transplant process safer and more effective for people with sickle cell disease.
This study tests a medication called fostamatinib to see if it is safe and tolerable for people with sickle cell disease. It may offer a new treatment option for managing the condition.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.